β blockers in heart failure
- 1 July 2003
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 362 (9377) , 2-3
- https://doi.org/10.1016/s0140-6736(03)13842-1
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The heart failure revascularisation trial (HEART): rationale, design and methodologyEuropean Journal of Heart Failure, 2003
- The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosisEuropean Heart Journal, 2003
- Myocardial Gene Expression in Dilated Cardiomyopathy Treated with Beta-Blocking AgentsNew England Journal of Medicine, 2002
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- What Type of β-Blocker Should Be Used to Treat Chronic Heart Failure?Circulation, 2000
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Beneficial effects of metoprolol in idiopathic dilated cardiomyopathyThe Lancet, 1993
- Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.Circulation, 1991